Your browser doesn't support javascript.
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
Tang, Wei; Cao, Zhujun; Han, Mingfeng; Wang, Zhengyan; Chen, Junwen; Sun, Wenjin; Wu, Yaojie; Xiao, Wei; Liu, Shengyong; Chen, Erzhen; Chen, Wei; Wang, Xiongbiao; Yang, Jiuyong; Lin, Jun; Zhao, Qingxia; Yan, Youqin; Xie, Zhibin; Li, Dan; Yang, Yaofeng; Liu, Leshan; Qu, Jieming; Ning, Guang; Shi, Guochao; Xie, Qing.
  • Tang W; Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Cao Z; Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Han M; Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Wang Z; Department of Respiratory Medicine, No 2 People's Hospital of Fuyang City, Fuyang, Anhui, China.
  • Chen J; Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei, China.
  • Sun W; Department of Respiratory and Critical Care Medicine, Xiangyang No 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China.
  • Wu Y; Department of Infectious Diseases, Central Hospital of Ezhou, Ezhou, Hubei, China.
  • Xiao W; Department of Cardiovascular Medicine, Yunmeng People's Hospital, Xiaogan, Hubei, China.
  • Liu S; Department of Respiratory Medicine, First People's Hospital of Jingzhou City, Jingzhou, Hubei, China.
  • Chen E; Department of Infectious Diseases, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China.
  • Chen W; Department of Emergency Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wang X; Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yang J; Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Lin J; Department of Respiratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Zhao Q; Department of Respiratory Medicine, Hubei Space Hospital of Xiaogan, Xiaogan, Hubei, China.
  • Yan Y; Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
  • Xie Z; Department of Infectious Disease, The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
  • Li D; Department of Infectious Disease, Wuhan No 7 Hospital, Wuhan, Hubei, China.
  • Yang Y; Departments of Respiratory Medicine, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China xieqingrjh@163.com.
  • Liu L; Department of Respiratory Medicine, The Third People's Hospital of Yichang, Yichang, Hubei, China.
  • Qu J; Department of Respiratory Medicine, Xiao Gan First People's Hospital, Xiaogan, Hubei Province, China.
  • Ning G; Clinical Research Centre, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shi G; Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Xie Q; Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
BMJ ; 369: m1849, 2020 05 14.
Article in English | MEDLINE | ID: covidwho-1495142
Semantic information from SemMedBD (by NLM)
1. hydroxychloroquine TREATS COVID-19
Subject
hydroxychloroquine
Predicate
TREATS
Object
COVID-19
2. hydroxychloroquine TREATS Patients
Subject
hydroxychloroquine
Predicate
TREATS
Object
Patients
3. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
4. COVID-19 PROCESS_OF Adult
Subject
COVID-19
Predicate
PROCESS_OF
Object
Adult
5. Adverse event PROCESS_OF Recipient
Subject
Adverse event
Predicate
PROCESS_OF
Object
Recipient
6. hydroxychloroquine ADMINISTERED_TO Participant
Subject
hydroxychloroquine
Predicate
ADMINISTERED_TO
Object
Participant
7. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
8. hydroxychloroquine TREATS COVID-19
Subject
hydroxychloroquine
Predicate
TREATS
Object
COVID-19
9. hydroxychloroquine TREATS Patients
Subject
hydroxychloroquine
Predicate
TREATS
Object
Patients
10. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
11. COVID-19 PROCESS_OF Adult
Subject
COVID-19
Predicate
PROCESS_OF
Object
Adult
12. Adverse event PROCESS_OF Recipient
Subject
Adverse event
Predicate
PROCESS_OF
Object
Recipient
13. hydroxychloroquine ADMINISTERED_TO Participant
Subject
hydroxychloroquine
Predicate
ADMINISTERED_TO
Object
Participant
14. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
ABSTRACT

OBJECTIVE:

To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).

DESIGN:

Multicentre, open label, randomised controlled trial.

SETTING:

16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.

PARTICIPANTS:

150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).

INTERVENTIONS:

Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration two or three weeks for patients with mild to moderate or severe disease, respectively). MAIN OUTCOME

MEASURE:

Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.

RESULTS:

Of 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval -10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events.

CONCLUSIONS:

Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients. TRIAL REGISTRATION ChiCTR2000029868.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Hydroxychloroquine Type of study: Controlled clinical trial / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: BMJ Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: Bmj.m1849

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Hydroxychloroquine Type of study: Controlled clinical trial / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: BMJ Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: Bmj.m1849